Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression - StreetInsider.com

Submitted by Anonymous (not verified) on Mon, 07/22/2024 - 12:01

Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression  StreetInsider.com